Follow @padstamundo

Research interest

Dr Patrick Harris is an Infectious Disease Physician and Medical Microbiologist, and is currently undertaking a PhD at The University of Queensland Centre for Clinical Research (UQCCR).    

Dr. Harris obtained a BSc in Psychology and Anthropology from Durham University, prior to acquiring his medical degree from University College London Medical School.  Following initial postgraduate training in the UK he worked as a clinical lecturer at the College of Medicine in Malawi, prior to completing specialist training in infectious diseases and microbiology in Australia.  For his final year of training he was a Senior Visiting Fellow in Infectious Disease at the National University Hospital in Singapore. He has published more than 26 peer-reviewed articles, most as first author, including recent publications in the Lancet, Lancet Infectious Diseases and Clinical Infectious Diseases. 

Research projects

Dr. Harris is currently undertaking a PhD with Professor David Paterson at UQCCR in the field of Gram-negative resistance, specifically undertaking clinical trials to help define optimal management of bloodstream infections caused by antibiotic-resistant pathogens. Current active projects include:

  1. 1. Randomised controlled trial of meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to third generation cephalosporin non-susceptible Escherichia coli and Klebsiella spp. (MERINO trial) – an international multicentre study to compare carbapenem-sparing treatment options for ESBL and AmpC-producing species.  This will be the first large RCT to specifically address this question, using a protocol developed and endorsed by the Australasian Society for Infectious Diseases Clinical Research Network (ASID-CRN). https://clinicaltrials.gov/ct2/show/NCT02176122

  2. 2. Pilot Randomised controlled trial of meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to AmpC-producing Enterobacter, Citrobacter, Serratia, Providencia and Morganella (MERINO-2 trial). https://clinicaltrials.gov/ct2/show/NCT02437045
  3. 3. The use of whole genome sequencing to characterise the resistome of Gram-negative pathogens causing bloodstream infections

Key publications

Paterson DL, Harris PN. The New Acinetobacter Equation: Hypervirulence Plus Antibiotic Resistance Equals Big Trouble. Clinical infectious diseases. 2015.

Harris PNA, Bich DL, Tambyah PA, Hsu LY, Pada S, Archuleta S, et al. Antiseptic body washes for reducing the transmission of methicillin resistant Staphylococcus aureus: a cluster cross-over study. Open Forum Infectious Diseases. 2015.

Harris PN, Yin M, Jureen R, Chew J, Ali J, Paynter S, et al. Comparable outcomes for beta-lactam/beta-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae. Antimicrobial resistance and infection control. 2015;4:14.

Harris PN, Tambyah PA, Paterson DL. beta-lactam and beta-lactamase inhibitor combinations in the treatment of extended-spectrum beta-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? The Lancet Infectious diseases. 2015;15(4):475-85.

Harris PN, Peleg AY, Iredell J, Ingram PR, Miyakis S, Stewardson AJ, et al. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial. Trials. 2015;16(1):24.

Harris PN, Alder L, Paterson DL. Antimicrobial susceptibility reporting and treatment selection for AmpC-producing Enterobacteriaceae: what do microbiologists and infectious disease practitioners actually practice? Pathology. 2015;47(4):386-8.

Harris P, Paterson D, Rogers B. Facing the challenge of multidrug-resistant gram-negative bacilli in Australia. The Medical journal of Australia. 2015;202(5):243-7.

Harris P. Clinical management of infections caused by Enterobacteriaceae that express extended-spectrum β-lactamase and AmpC enzymes. Seminars in Respiratory and Critical Care Medicine. 2015

View full list of publications